# A bleeding heart: case report and review of pericardial angiosarcoma

**Authors:** Ujjwal Madan, Himil Mahadevia, Parth Sharma, Satya Preetham Gunta, Ossama Tawfik, Karen Fritchie, Julian Magadan

PMC · DOI: 10.4322/acr.2024.488 · Autopsy & Case Reports · 2024-05-22

## TL;DR

This paper presents a rare case of pericardial angiosarcoma and emphasizes the importance of early diagnosis and multimodal treatment for better outcomes.

## Contribution

The paper highlights the diagnostic challenges and treatment approach for pericardial angiosarcoma through a case report and literature review.

## Key findings

- Pericardial angiosarcoma is rare and has a poor prognosis with a median survival of 25 months.
- Multimodal treatment improves outcomes compared to single-modality treatment.
- Early diagnosis using cardiac imaging and biopsy is crucial for better survival.

## Abstract

Primary cardiac tumors are rare. The cardiac sarcomas are the most common malignant cardiac tumors. These tumors have a dismal prognosis with an overall median survival of 25 months. Clinical features include dyspnea, arrhythmias, pericardial effusions, heart failure, and sudden cardiac death.

The diagnosis is often challenging. Therefore, the cardiac imaging workup plays a central role in addition to a high clinical suspicion in the setting of atypical presentations that do not respond to standard therapies. The echocardiography, computed tomography, and cardiac MRI are crucial in clinching the diagnosis. Multimodal treatment with surgery, chemotherapy, and radiotherapy has been shown to improve outcomes, as opposed to using either of these modalities alone. We describe the case of a 30-year-old gentleman with COVID-19 infection who developed recurrent hemorrhagic pericardial effusions refractory to standard treatment and was eventually diagnosed as a case of pericardial angiosarcoma after his biopsy revealed the diagnosis and staging was performed using PET–CT–FDG scan. Our case re-emphasizes the importance of considering a malignant etiology early in the course of the disease presentation, especially in recurrent hemorrhagic effusions despite an inflammatory cytologic diagnosis of fluid. It also highlights the place for cardiac CT and MRI to ascertain the location and spread and to plan the further course of treatment. If diagnosed early, the estimated survival time can be prolonged by instituting a multimodal approach.

## Linked entities

- **Chemicals:** doxorubicin (PubChem CID 31703)
- **Diseases:** heart failure (MONDO:0005252), sudden cardiac death (MONDO:0007264), COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** heart failure (MESH:D006333), arrhythmias (MESH:D001145), pericardial effusions (MESH:D010490), inflammatory (MESH:D007249), cardiac tumors (MESH:D006338), sudden cardiac death (MESH:D016757), dyspnea (MESH:D004417), COVID-19 infection (MESH:D000086382), tumors (MESH:D009369), hemorrhagic (MESH:D006470), pericardial angiosarcoma (MESH:D006394), bleeding heart (MESH:D006331)
- **Chemicals:** FDG (MESH:D019788)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11129860/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11129860/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC11129860/full.md

---
Source: https://tomesphere.com/paper/PMC11129860